Impact Biomedical to execute 1-for-12.62 reverse stock split Sept. 23
Reuters2026/09/15 01:27- Impact Biomedical set a 1-for-12.62 reverse stock split, effective Sept. 23, 2026.
- Shares will continue trading on NYSE American under IBO.
- Outstanding shares expected to drop to about 8,543,679 from about 107,821,231, subject to rounding.
- Merger terms with Zoar call for 1 Zoar share per 1 Impact share, calculated post-split.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
VIX soars to 18, options volume doubles: traders bet "AI risks are scarier than Fed rate hikes"
US equities options traders believe that debates over the pace of AI development pose a greater disruptive risk than Federal Reserve rate hikes. The volume of VIX options has doubled, with funds aggressively hedging against the risk of sharp fluctuations in technology stocks.
GLJ gives GE Vernova (GEV.US) a "Sell" rating: $470 target price is the lowest on Wall Street, bluntly stating that "cyclical industrial stocks are being priced like software stocks"
GLJ Research has given GE Vernova a "sell" rating and set the lowest target price on Wall Street at $470, stating that the company is "a cyclical gas turbine manufacturer priced like a long-term compound growth stock."
Data: US XRP spot ETF saw a net inflow of 11.255 million USD in a single day
Delta Thailand returns to FTSE4Good ESG index for eighth time
Crypto prices
More
